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Abstract: BACKGROUND Bioresorbable vascular scaffolds (BVS) have become an emerging tool to treat
coronary artery disease. However, the current use of BVS is still widely restricted to stable patients and
non-complex lesions. In real-world practice patients are far more complex than those with simple type
A lesions and the extended use of BVS to complex lesions and high-risk patients needs to be evaluated.
Therefore, we sought to investigate the feasibility and performance of BVS in a broad spectrum of
patients. METHODS 106 patients underwent in total 193 BVS implantations. We assessed the device-
related (cardiac death, target vessel myocardial infarction, ischemia-driven target lesion revascularization)
and patient-related (all-cause death, any reinfarction and any revascularization) composite outcomes.
RESULTS 90 % of patients (n = 95) had at least one of the following characteristics: >65 years (35 %),
ACS (42 %), tortuous vessels (13 %), calcified (17 %) or thrombotic lesions (12 %), lesions defined as
AHA type B2/C (42 %), bifurcations (16 %), chronic total occlusions (9 %) or restenosis (14 %). There
was no evidence of significant edge dissection, huge thrombus load or incidence of scaffold dislodgement
or scaffold disruption in optical coherence tomography pullbacks. Out of 10,157 struts evaluated within
1,117 cross-sections, 302 were classified as malapposed (2.9 %). During a mean follow-up of 147 ± 119
days the rate of device-related events was 2.0 %, whereas patient-related composite events occurred in 6.1
%. CONCLUSIONS Our results strongly suggest that BVS implantation is feasible in a wide spectrum
of patients and complex anatomy of coronary lesions. Long-term outcome of BVS should be further
investigated in unrestricted settings in randomized controlled trials.
DOI: https://doi.org/10.1007/s00392-014-0757-4





Jaguszewski, Milosz; Ghadri, Jelena-Rima; Zipponi, Manuel; Bataiosu, Dana Roxana; Diekmann, Jo-
hanna; Geyer, Verena; Neumann, Catharina Anna; Huber, Mia Aurelia; Hagl, Christian; Erne, Paul;
Lüscher, Thomas F; Templin, Christian (2014). Feasibility of second-generation bioresorbable vascular




Feasibility of second-generation bioresorbable vascular scaffold
implantation in complex anatomical and clinical scenarios
Milosz Jaguszewski • Jelena-Rima Ghadri • Manuel Zipponi • Dana Roxana Bataiosu •
Johanna Diekmann • Verena Geyer • Catharina Anna Neumann • Mia Aurelia Huber •
Christian Hagl • Paul Erne • Thomas F. Lüscher • Christian Templin
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Abstract
Background Bioresorbable vascular scaffolds (BVS)
have become an emerging tool to treat coronary artery
disease. However, the current use of BVS is still widely
restricted to stable patients and non-complex lesions. In
real-world practice patients are far more complex than
those with simple type A lesions and the extended use of
BVS to complex lesions and high-risk patients needs to be
evaluated. Therefore, we sought to investigate the feasi-
bility and performance of BVS in a broad spectrum of
patients.
Methods 106 patients underwent in total 193 BVS
implantations. We assessed the device-related (cardiac
death, target vessel myocardial infarction, ischemia-driven
target lesion revascularization) and patient-related (all-
cause death, any reinfarction and any revascularization)
composite outcomes.
Results 90 % of patients (n = 95) had at least one of the
following characteristics:[65 years (35 %), ACS (42 %),
tortuous vessels (13 %), calcified (17 %) or thrombotic
lesions (12 %), lesions defined as AHA type B2/C (42 %),
bifurcations (16 %), chronic total occlusions (9 %) or
restenosis (14 %). There was no evidence of significant
edge dissection, huge thrombus load or incidence of scaf-
fold dislodgement or scaffold disruption in optical coher-
ence tomography pullbacks. Out of 10,157 struts evaluated
within 1,117 cross-sections, 302 were classified as malap-
posed (2.9 %). During a mean follow-up of
147 ± 119 days the rate of device-related events was
2.0 %, whereas patient-related composite events occurred
in 6.1 %.
Conclusions Our results strongly suggest that BVS
implantation is feasible in a wide spectrum of patients and
complex anatomy of coronary lesions. Long-term outcome
of BVS should be further investigated in unrestricted set-
tings in randomized controlled trials.
Keywords Bioresorbable vascular scaffold  Optical
coherence tomography
Introduction
The first plain-old balloon angioplasty (POBA) performed
by Andreas Gruentzig in 1977 in Zurich, Switzerland,
revolutionized the treatment strategy of coronary artery
disease (CAD) [1]. The common acute and chronic recoil
was reduced by the subsequent introduction of bare-metal
stents (BMS), as reported in the BENESTENT trial [2].
However, as the restenosis rate remained high with BMS,
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drug-eluting stents (DES) were developed. Although the
first-generation DES essentially reduced the need for
urgent revascularization as compared to BMS, their pro-
pensity for late stent thrombosis (ST) was a concern [3].
Furthermore, the need for target lesion revascularization
after DES implantation remains a still not fully resolved
issue. The design of new second-generation DES with
biocompatible polymer coatings allowed for improved
deliverability, endothelial healing and therefore better
device-rated outcomes [4]. Nowadays, the new technol-
ogy of bioresorbable vascular scaffolds (BVS) remains a
ray of hope in the field of interventional cardiology.
Nonetheless, data are still lacking regarding their use in a
real-world setting. Indeed, so far these novel scaffolds
have been exclusively used in stable patients with non-
complex lesions [5–8]. Currently, only little data exist
regarding real-world use of these devices, i.e., in patients
with acute coronary syndromes (ACS), chronic total
occlusions (CTO), bifurcations, and restenosis [9–13]. We
therefore aimed to investigate the clinical outcome after
BVS implantation in two highly experienced centers in a
wide patient spectrum.
Methods
Population, data collection, and procedures
The study flowchart is presented in Fig. 1. Patients from
two Swiss tertiary cardiology centers (University Heart
Center, Cardiology, Zurich and Cardiology, Regional
Hospital Lucerne) with stable CAD or ACS who qualified
for percutaneous coronary intervention (PCI) were enrolled
from September 2012 to December 2013. Eligible patients
had at least one coronary artery lesion and no restrictions as
to the number, severity and location of stenosis. All
patients were implanted with at least one second-genera-
tion BVS (Abbott Vascular, Santa Clara, California)
designed with semicrystalline poly-L-lactide (PLLA) and
coated with an amorphous poly-D, L-lactide (PDLA) poly-
mer eluting everolimus. The reason for the selection of
BVS was left to the discretion of the operator. Medical
records including demographics, clinical, angiographic and
procedural features were collected with the use of special
electronic databases. The use of anonymized data, origi-
nating from retrospective analysis of personal data from
own patients exclusively, requires no approval by the local
ethics committee.
The intervention was obtained according to the current
PCI guidelines. All lesions were prepared with the use of
balloon dilatation before each BVS implantation and BVS
deployment was performed in line with the manufacturer’s
recommendations at a rate of 2 atmospheres per 5 s up to
rated burst pressure. If more than one BVS was implanted,
the overlap technique or adjacent-positioning technique
was used.
Coronary angiography was performed in the left cor-
onary system with two radiation exposures in four pro-
jections and in the right coronary artery with two
exposures in two projections. Lesions were classified
according to the AHA/ACC criteria as follows—type A:
minimally complex, concentric, readily accessible of
length \10 mm in non-angulated segment (\45), with
little or no calcification, less than totally occlusive, not
ostial in location, with no major side branch (SB)
involvement, and no apparent thrombus; type B1: mod-
erately complex, with a length of 10-20 mm, eccentric
and with irregular contour, moderate or heavy calcifica-
tion in a proximal segment of moderate tortuosity, mod-
erately angulated ([45 and \90), total occlusions
\3 months old, ostial in location, and bifurcation lesions
requiring double guidewires with some thrombus present;
type B2: lesions demonstrating two or more type B1
characteristics; type C: severely complex, with length of
[20 mm, in a tortuous, proximal, extremely angulated
segment, total occlusions[3 months old and/or bridging
collaterals, and degenerated vein grafts.
Patients were treated with dual antiplatelet therapy
(DAPT) comprising a loading dose of aspirin 500 mg i.v.,
followed by the maintained daily dose of 100 mg, and
clopidogrel 600 mg p.o. followed by the maintained daily
dose of 75 mg for 12 months or prasugrel 60 mg p.o.
continued with 10 mg daily dose or ticagrelor 180 mg
loading dose and continued with 2 9 90 mg daily dose.
Heparin was administered intravenously to maintain the
activated clotting time of at least 250 s. The use of
thrombectomy and GP IIb/IIIa administration was at the
discretion of the respective cardiologist. Manual
Fig. 1 Temporal trends in patients’ age and lesion characteristic for
the usage of BVS
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thrombectomy was performed using an Export catheter
(Medtronic Inc., Minneapolis, USA).
Definitions
ST-segment elevation myocardial infarction (STEMI) was
defined as a new ST-segment elevation of at least 1 mm
in two or more contiguous leads or new left bundle branch
block (LBBB) concomitant with elevated troponin level
[14]. Non-ST-segment elevation myocardial infarction
(NSTEMI) was defined as the elevation of biomarkers of
myocardial necrosis (e.g., troponin) with no evidence of
ST-segment elevation in the ECG in the presence of
angina chest pain [15]. CTO was defined as a complete
obstruction of coronary artery with thrombolysis in
myocardial infarction (TIMI) flow grade 0 and an esti-
mated time of occlusion of at least 3 months [16]. Target
lesion revascularization (TLR) was defined as repeat
intervention in a de novo lesion within the stented seg-
ment with a luminal diameter of C50 % or within a 5 mm
border zone proximal or distal to the stent. An ‘‘off-label
indication’’ was defined as a BVS implantation in patients
[65 years, those referred for primary PCI due to an ACS,
in tortuous vessels, calcified or thrombotic lesions, lesions
defined as AHA type B2/C, bifurcation lesions, CTO, and
in restenosis.
Optical coherence tomography (OCT)
The C7-XR OFDI system (LightLab Imaging, Inc, St Jude
Medical, St. Paul, MN, USA) was optionally used to
acquire images during intracoronary injection of contrast
media with an optical fiber Dragonfly or Dragonfly Duo
catheter. The Dragonfly catheter was positioned over a
conventional 0.0140 angioplasty guidewire and automated
pullback (20 mm/s), with an image acquisition at 100
frames/s, and contrast injection (6 mL/s) was used to
acquire all images.
All pullbacks were analyzed post hoc in our core
laboratory of the Andreas Gruentzig Catheterization
Laboratories at the University Heart Center, University
Hospital of Zurich, Switzerland using proprietary software
(ILUMIEN OPTIS system, Inc, St Jude Medical, St. Paul,
MN, USA). The analysis was performed in 1 mm longi-
tudinal intervals within treated segments and 5 mm
proximal and distal. Image quality was assessed using a
four-point scale (excellent, good, moderate, non-diagnos-
tic) and only excellent pullbacks, i.e., with [95 % of
cross sections with full lumen contour visibility, were
included in the final analysis. All BVS were investigated
with regard to strut apposition, strut fracture, edge dis-
sections, and thrombus formations. Every single strut was
analyzed in each OCT frame. Struts were considered
malapposed when the abluminal surface was separated
from the vessel wall.
Three-dimensional reconstructions of OCT were per-
formed for an optimal visualization of bifurcations. Ostia
of all side branches of[1.5 mm diameter were assessed
visually and classified as follows: non-jailed SB, when no
compartments were present in the SB orifice; jailed SB,
when BVS struts separated the orifice of SB into com-
partments with different patterns (V, T, H, and double T) as
described previously [17].
Edge dissection of[30 % of lumen circumference was
considered as significant. Procedural strut fracture was
defined if two struts overhung each other in the same
angular sector of the lumen and/or if struts were located in
the lumen without any connection with other struts [18].
The use of OCT was left at the discretion of the operator
and was especially used in case of a large thrombus burden,
Table 1 Baseline characteristics
Baseline characteristics (n = 106)
Age 61.0 ± 10.7
Gender (male) 81 (76.4)
BMI (kg/m2) 27.5 ± 3.5














LVEF 59.3 ± 13.3
LVEDP 17.9 ± 7.3
HR 71.5 ± 15.5
SBP 130.8 ± 23.3




Depicted are counts, n, incidence (%) or mean ± SD
ACS acute coronary syndrome, BMI body mass index, DBP diastolic
blood pressure, DM diabetes mellitus, FH known family history, GP
glycoprotein llb/llla inhibitor, HR heart rate, LVEF left ventricle
ejection fraction, LVEDP left ventricle end-diastolic pressure, MI
myocardial infarction, SBP systolic blood pressure, STEMI ST-seg-
ment elevation myocardial infarction
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in STEMI patients, bifurcations, and to track the BVS
implantation after CTO recanalization. We intended to
avoid OCT evaluation in patients with hemodynamic
deterioration and chronic renal failure. OCT evaluation was
performed by the investigator blinded to the clinical
characteristics and outcome.
SYNTAX score
SYNTAX score assessment was performed by a cardiolo-
gist blinded to the clinical characteristics and outcomes of
the patients using a scoring system for all significant
lesions (C50 %) in the vessels C1.5 mm in diameter using
the SYNTAX score algorithm. The SYNTAX score was
calculated using angiography just after the first dilatation of
the culprit vessel, thereby allowing inclusion of all sig-
nificant lesions [19].
Outcomes
Follow-up analysis included device-related composite
outcome measures of cardiac death, target vessel myocar-
dial infarction, ischemia-driven TLR, and patient-related
outcome measure of all-cause death. Any reinfarction and
any revascularization was collected routinely by using
standardized clinical questionnaire for hospital quality
assessment. Furthermore, we evaluated the rate of ische-
mia-driven TLR and definite/possible/probable scaffold
thrombosis.
Statistics
Data are presented as percentages mean ± SD. Categorical
variables were compared with Chi square test. A
p value\ 0.05 was considered to be statistical significant.
Fig. 2 BVS in type A lesion. Type A lesion in the middle portion of
the right coronary artery (a and b) predilated with a 3.0 9 15 mm
balloon and subsequently covered by 3.5 9 20 mm BVS (c) with
excellent angiographic result (d). The OCT pullback documented
well-apposed struts in all cross sections (e-g)




Patients’ baseline characteristics are presented in Table 1.
The average age was 61.0 ± 10.7 years with only 35 %
patients (n = 37) being older than 65 years. PCI was
successfully performed in all patients (n = 106). Full
revascularization was obtained in 87 % of patients
(n = 92). Mean left ventricular ejection fraction was
59.3 ± 13.3 %. Four percent of patients (n = 4) required
GP IIb/IIIa infusion and in 13 % (n = 14) manual throm-
bectomy was performed. The study flowchart has been
presented on Supplementary Fig. 1.
BVS implantation and OCT
In total, 193 BVS were implanted with an average amount
of 1.82 ± 1.19 per patient and average length of
42.6 ± 30.7 mm per patient. The minimal length of
implanted BVS was 18 mm and the maximal length
186 mm (7 BVS in one patient). The scaffold diameters
used were 2.5, 3.0 and 3.5 mm. The mean SYNTAX score
was 14.4 ± 10.6 (range 1-51). The implantation of BVS
was extended to more acute situations with increasing
experience of the operators (Fig. 1). Out of 139 lesions
covered by BVS, 25 % (n = 34) were defined as type A
(Fig. 2) and 34 % (n = 47) as type B1. 90 % of patients
(n = 95) had at least one of the following characteristics:
[65 years (35 %), ACS (42 %), tortuous vessels (13 %),
calcified (17 %) or thrombotic lesions (12 %), lesions
defined by AHA type B2/C (42 %), bifurcations (16 %),
CTO (9 %), or restenosis (14 %) (Table 2). Three patients
with coronary dissection received BVS. The procedural
success rate was 97 %. TIMI 3 flow grade was restored in
all patients. Three BVS were not implanted due to the
inability to pass the lesion. These patients were excluded
from the final analysis. In two cases coronary artery rupture
occurred and was successfully covered by stent graft
implantation.
OCT was performed at the end of PCI in 36 of the 106
patients (34 %) in which BVS implantation was considered
most challenging and high risk, i.e., after CTO recanalization
(Fig. 3), in long left anterior descending artery dissection
(Fig. 4), in-stent restenosis (Fig. 5) and bifurcations (Fig. 6)
and in patients with thrombotic occlusion during an STEMI
event (Fig. 7). Six pullbacks were excluded due to the sub-
optimal imaging quality. All OCT pullbacks and cross-sec-
tions showed an excellent result after BVS implantation,
with no evidence of significant postprocedural edge dissec-
tion, huge thrombus load, incidence of scaffold dislodge-
ment, or scaffold disruption.
Out of 10,157 struts evaluated within 1,117 cross-sec-
tions from 30 remaining patients, 302 were classified as
malapposed (2.9 %). Only in eight patients the rate of
malapposed struts was[5 %. Protruding residual thrombus
formations after PCI were apparent significantly more often
in patients referred for invasive treatment due to ACS
compared with non-ACS patients (ACS vs. non-ACS
patients: 47.5 % cross-sections vs. 37.2 % cross-sections,
p\ 0.001). Three-dimensional reconstruction of OCT
pullbacks documented 45 SB of diameter[1.5 mm covered
by the scaffold struts, out of which 41 were available for
evaluation. The different patterns of compartmentalization
were recorded as follows: 20 % non-jailed SB (n = 8),
17 % V-type jailed SB (n = 7), 39 % T-type jailed SB
(n = 16), 17 % H-type jailed SB (n = 7), and 7 % double
T-type jailed SB (n = 3).
Follow-up
Complete follow-up was available in 92 % patients (n = 98).
The mean follow-up period was 147 ± 119 days. The rate of
patient-related outcome (MACE) was 6.1 % (n = 6) and
device-related outcome 2.0 % (n = 2) (Table 3).




Single-vessel disease 44 (41.5)
Multivessel disease 62 (58.5)
SYNTAX score 14.4 ± 10.6
Full revascularization 92 (86.8)
TIMI flow 0 at baseline 22 (20.8)
TIMI flow 3 after PCI 106 (100)
Lesions treated by BVS 139
Type A 34 (24.5)
Type Bl 47 (33.8)
Type B2 34 (24.5)
Type C 24 (17.2)
BVS implanted per patient 1.82 ± 1.19
Unrestricted indications
Chronic total occlusion 10 (9.4)
Restenosis 15 (14.2)
Bifurcations 17 (16.0)
Heavy calcifications 18 (17.0)
Thrombus 13 (12.3)
Tortuous vessel 14 (13.2)
Depicted are counts, n incidence (%) or mean ± SD
TIMI thrombolysis in myocardial infarction
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Two patients died, one of cardiovascular cause. One patient
underwent urgent CABG, while two patients had defi-
nite scaffold thrombosis (one acute and one subacute scaffold
thrombosis). The acute scaffold thrombosis has been docu-
mented by OCT [20]. No possible/probable scaffold throm-
bosis was documented in this subset.
Discussion
Our preliminary experience with the use of second-gener-
ation everolimus-eluting BVS in a wide patient spectrum
suggests that these novel scaffolds are feasible and effica-
cious even in unstable patients and complex lesions.
Fig. 3 BVS in true chronic
total occlusion. Elective
recanalization of a chronic total
occlusion of the right coronary
artery (RCA) (a). After crossing
the CTO with a pilot guidewire
and an extensive vascular
sealing with an Avion-Plus
1.25 9 20 mm balloon,
Maverick 2.0 9 20 mm balloon
and Maverick 2.5 9 30 mm
balloon (b, dissection—white
arrow), two BVS 2.5 9 28 mm
were implanted in the distal and
medial portion of the RCA.
Subsequently, after catheter
exchange (AL1-to-JR4-side-
holes) and BMW guidewire
placement, the predilatation of
the proximal and ostial portion
of the RCA was obtained with
the use of a Maverick
3.0 9 15 mm balloon. Finally,
the third BVS 3.0 9 18 mm
was implanted to cover the
ostial part of the RCA (c and d).
The OFDI demonstrated an
optimal postprocedural result
(d-l) with well-apposed
scaffold struts (e-i) and full
coverage of iatrogenic
dissections after the
recanalization. The thickness of
two overlapping struts was
300 lm (f and i, pullback—
Supplemental video 1). The
OFDI after 5-month follow-up
demonstrated full coverage of
BVS struts (j-n, pullback—
Supplemental video 2) and an
optimal result in angiography
(o-r)
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Indeed, the unrestricted use of BVS at both institutions
included also elderly patients, those with ACS and/or
complex lesions including chronic total occlusions, mas-
sive calcifications, restenosis, and bifurcation lesions.
Currently, the most commonly used second-generation
DES with advanced design features shows a substantial
reduction in adverse outcomes when compared with first-
generation paclitaxel- or sirolimus-eluting stents and in
particular BMS. The permanent metal structure of current
stents prevents the recoil process and negative remodeling.
However, the metal alloy remains a source of inflammation
predisposing to neoatherosclerosis and ST and prevents
normal coronary vasomotion during episodes of increased
demand [21, 22].
These remaining disadvantages of metal scaffolding
prompted the exploration of better treatment strategies in
patients with CAD. The potential advantage of bioab-
sorbable scaffolds is the fact that the foreign body only
transiently remains present, allowing for proper healing
and later normal coronary vasomotion. Furthermore,
implantation of bypass grafts remains possible, if later on
required. Indeed, the current lactic acid BVS resolves
within 2-3 years [23]. Also, first experiences including a
few patients with simple lesions were published using
other scaffolds, i.e., absorbable metal scaffolds [24, 25].
In contrast to earlier bioabsorbable magnesium stents [24],
the everolimus-eluting BVS retains important features of
second-generation DES. The bioabsorption of the lactic
acid scaffold may result in a reduction of chronic
inflammation processes, thereby reducing vessel irritation
and restoration of natural vascular function and positively
influencing the blood velocity as well as endothelial shear
stress [26].
Second-generation BVS has been designed to overcome
limitations of metal stents including permanent double
layers of struts, struts at the side branch ostium, and stent
under deployment due to vasoconstriction or thrombus
sequestration. However, data regarding the potential use of
BVS in bifurcation lesions and in emergency cases are still
scarce. No original data are available, i.e., to affirm the
performance of BVS to pass the struts of a previously
implanted scaffold in the main branch. In our work we
present the feasibility of the BVS T-stenting technique
regardless of its relatively high crossing profile.
Fig. 4 BVS in a long dissection in young adult. Non-ST segment
elevation myocardial infarction with long dissection starting in the
middle portion of the left anterior descending artery (LAD) (a and b).
After thrombectomy and extensive dilatation with a 2.5 9 30 mm
balloon, five BVS were implanted (three times 2.5 9 28 mm,
3.0 9 28 mm, and 3.5 9 28 mm) (c). The OCT documented a
satisfactory result in the LAD (d-j); (pullback—Supplemental video
3)
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Furthermore, BVS may be an option in patients with
stent restenosis requiring stent-in-stent implantation,
contraindications to prolonged DAPT, and those with
long lesions [27]. Although, the scaffold seems to be
covered by endothelial cells early on after implantation,
the requirement of prolonged DAPT after BVS implan-
tation is still uncertain. In patients with in-stent reste-
nosis, no-flow limiting dissections, and acceptable non-
stent like primary result, the use of drug-coated balloons
(DCB) is one of the possible therapy options. DCB could
be also a considered in case of contraindications for
prolonged DAPT. Unfortunately, POBA by itself has
many limitations including, i.e., flow-limiting dissections.
Moreover, DCB could not control the elastic recoil after
PCI when no stent was implanted. Thus, BVS might be
more efficient in thrombotic lesions, after plaque rup-
tures, in flow-limiting dissections, and especially in
young patients.
Although currently not recommended, BVS may repre-
sent the treatment of choice also in patients with CTO, in
which commonly the entire vessel is affected by the
atherosclerotic process. However, data regarding the safety
and performance in a wide spectrum of population is still
limited. Particularly, scaffold overlap has been hypothe-
sized to be prone to the delayed healing process, due to a
thickness of minimum 300 lm. In our representative case
of CTO treated with BVS, full strut coverage was docu-
mented after 5 months of follow-up (Fig. 3) despite the
strut malapposition rate of 7.1 % within three scaffolds of a
summarized length of 74 mm.
Of note, in our real-world population, the MACE rate
was comparable with that reported for the unrestricted use
of second-generation DES [28]. The high rate of ST
(2.1 %) observed in our population may be related to a
suboptimal lesion preparation and/or malapposed scaffolds
[20]. In patients with ST, the scaffold was indeed incor-
rectly implanted as documented by OCT. In our experi-
ence, ST occurred in an elderly patient referred for primary
PCI due to ACS, where BVS was implanted in a heavily
calcified LAD [20].
Currently, the applicability of BVS in calcified lesions is
a matter of debate. Most physicians are still skeptical with
Fig. 5 BVS in in-stent-stenosis. BVS implantation in a stent
restenosis of a bifurcation lesion after biolimus-eluting stent implan-
tation in the middle portion of the circumflex artery (LCx) (a and b).
After extensive predilatation in the marginal branch and LCx with
2.5 9 15 mm and 2.5 9 30 mm drug-eluting balloons, a
2.5 9 28 mm BVS was implanted. Due to small edge dissection
after BVS implantation, a second 3.0 9 18 mm BVS was used to
cover the proximal portion of the LCx (c). OCT pullback recorded an
excellent postprocedural result (d-j); (pullback—Supplemental
video 4)
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regard to the device deliverability and radial strength [29].
Indeed, unlike the currently used DES, the deliverability of
BVS seems more challenging due to the strut thickness of
150 lm and crossing profile of 1.4 mm [30]. However, the
new BVS (ABSORB 1.1) currently on the market has
several modifications as compared to the previous one
(ABSORB 1.0) investigated in cohort A. Also, the polymer
underwent several modifications related to the polymer
processing, improved device retention, and scaffold design
to give more prolonged radial support [31]. Stents should
be designed to withstand the difference between the
transluminal and intraluminal pressures up to 175 mmHg.
Thus, concerning the safety issues, the minimal acceptable
collapse pressure for stents is 300 mmHg [32, 33]. Fur-
thermore, the lumen of the vessel appears to stabilize
approximately 3 months after PCI [34].
Another downside of current BVS is the fact that they
are radiolucent, except for platinum markers. Thus, in cases
with long and/or calcified lesions, accurate lesion prepa-
ration including the use of noncompliant balloons appears
advisable. Furthermore, subsequent intravascular imaging
should be obtained to avoid incomplete scaffold apposition.
Potential malapposition can be immediately sealed by
accurate balloon post dilatation. Post dilatation, however,
should be performed with caution, since overexpansion
may fracture struts and disrupt BVS [35]. Despite the wide
patient spectrum in this study, the result with regard to strut
malapposition was comparable with the OCT substudy of
cohort B, where no complex patients were enrolled
(p = 0.13) [36].
The main limitation of the study was its observational
nature, based on the double-center cohort. We did not
Fig. 6 BVS-T stenting of a bifurcation lesion. Bifurcation lesion in
acute coronary syndrome and slow flow in left anterior descending
artery (LAD, a and b). After passing the lesion with a BMW
guidewire, manual thrombectomy, and vascular sealing with a
Maverick 2.5 9 15 mm balloon, a BVS 3.0 9 18 mm was implanted
in the middle portion of the LAD and extended by a second BVS
3.0 9 12 mm. The second BMW guidewire was retrieved to the
bifurcation of the second diagonal branch (DA2) and advanced again
through the struts of the previously implanted BVS. After subsequent
dilatation in the ostial portion of the DA2 with a Maverick
2.5 9 15 mm balloon, a BVS 2.5 9 12 mm was gently positioned
through the BVS struts to seal the iatrogenic dissection (c and d). The
final angiogram (e) and optical coherence tomography (OCT) (f-
n) demonstrated an optimal postprocedural result with well-apposed
struts in all cross sections (e-m); (pullback—Supplemental video 5).
*Dissection in DA2; **protruding thrombi inapparent in angiography;
***BMW guidewire to DA2
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include a control group and the follow-up period differed
between patients. The follow-up was not prespecified and
no minimal observation time period was required. DES
were additionally implanted in 26 patients, which could
have impact on outcome. The implantation of DES was
left to the operator‘s discretion.
Conclusions
In summary, our study demonstrates the feasibility and good
performance of BVS in an unselected population including
patients with ACS and complex coronary anatomy. The use
of BVS may be feasible in patients at high risk of restenosis,
particularly after extensive stent implantation of target ves-
sel and with a history of diabetes mellitus. Nonetheless, in
high-risk patients, i.e., referred for primary PCI due to
STEMI and thrombotic lesion including left main and ostial
LAD, we suggest an adequate lesion preparation and the use
of intravascular imaging to prevent malapposition and
device-related adverse events.
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